Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Pharmacogenet Genomics. 2016 Oct;26(10):473–480. doi: 10.1097/FPC.0000000000000238

Table 2. Primary reason for discontinuation of efavirenza.

Cause Number of cases
(n = 99)
Percentage
Central nervous system symptoms 29 29.3
Rash 23 23.2.
Viral drug resistance mutations 16 16.2
Non-adherence 9 9.1
Gastrointestinal side effects 6 6.1
Drug-drug interaction 2 2.0
Hypercholesterolemia 2 2.0
Other 2 2.0
Unspecified 10 10.1
a

Based on review of provider notes in the electronic medical record.